Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.5693
-0.0355-5.87%
Post-market: 0.5620-0.0073-1.28%19:44 EDT
Volume:531.81K
Turnover:303.84K
Market Cap:22.48M
PE:-0.30
High:0.6114
Open:0.5900
Low:0.5593
Close:0.6048
52wk High:5.14
52wk Low:0.4300
Shares:39.50M
Float Shares:30.75M
Volume Ratio:1.63
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9003
EPS(LYR):-1.6652
ROE:-101.55%
ROA:-55.53%
PB:0.44
PE(LYR):-0.34

Loading ...

VistaGen director Mary Rotunno resigns effective April 1, 2026

Reuters
·
Mar 19

Class action lawsuit targets VistaGen over alleged misleading fasedienol trial statements

Reuters
·
Mar 13

BUZZ-Vistagen cuts 20% of staff to extend cash runway, shares fall

Reuters
·
Mar 11

Class action lawsuit targets VistaGen Therapeutics over alleged misleading clinical trial statements

Reuters
·
Mar 11

BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction

Reuters
·
Mar 11

VistaGen Therapeutics implements 20% workforce reduction

Reuters
·
Mar 11

Vistagen Therapeutics Inc - Affected Employees May Receive Cash Severance and Temporary Healthcare Coverage - SEC Filing

THOMSON REUTERS
·
Mar 11

Vistagen Therapeutics Inc - Expects Costs From Workforce Reduction to Be Immaterial - SEC Filing

THOMSON REUTERS
·
Mar 11

Class Action Lawsuit Targets VistaGen Therapeutics Over Misleading Trial Claims

Reuters
·
Mar 05

Pomerantz Files Securities Class Action Against VistaGen Therapeutics

Reuters
·
Mar 04

VistaGen to Participate in Leerink Healthcare Conference and Stifel 2026 Virtual CNS Forum

Reuters
·
Mar 03

Schall Law Firm Files Securities Fraud Class Action Against VistaGen Therapeutics

Reuters
·
Mar 03

Class Action Lawsuit Targets VistaGen Therapeutics and Officers

Reuters
·
Mar 03

Rosen Law Firm Alerts VistaGen Investors to March 16 Lead Plaintiff Deadline in Securities Class Action

Reuters
·
Mar 02

VistaGen to Present Corporate Overview at 46th Annual TD Cowen Healthcare Conference

Reuters
·
Feb 25

Rosen Law Firm Urges VistaGen Investors to Act Ahead of March 16 Lead Plaintiff Deadline

Reuters
·
Feb 25

Securities Fraud Class Action Filed Against VistaGen Therapeutics

Reuters
·
Feb 24

Levi & Korsinsky Files Securities Class Action Against VistaGen Therapeutics

Reuters
·
Feb 24

VistaGen Director Paul Edick Resigns from Board

Reuters
·
Feb 20

Class Action Lawsuit Targets VistaGen Therapeutics Over Investor Claims

Reuters
·
Feb 20